Drug Profile
Research programme: antibacterial agents - Sequoia Sciences
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sequoia Sciences
- Class Antibacterials; Small molecules
- Mechanism of Action Fimbriae protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections; Pseudomonal infections
- Discontinued Staphylococcal infections; Streptococcal infections
Most Recent Events
- 05 Sep 2023 Preclinical development for Gram-negative infections is ongoing in USA (Sequoia Sciences pipeline, September 2023)
- 05 Sep 2023 Preclinical development for Pseudomonal infections is ongoing in USA (Sequoia Sciences pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Staphylococcal infections in USA (unspecified route) (Sequoia Sciences pipeline, September 2023)